Second-generation basal insulins improve glycaemic control

Second generation basal insulin revolution - Home page 2nd line

Second-generation basal insulins are particularly beneficial to diabetes patients with marked variability in glucose levels, frequent all-day and/or nocturnal hypoglycaemia despite optimisation of current insulin analogue regimen

You will gain an understanding and awareness of:

  • The fundamental principles of an integrated approach to diabetes treatment with the goal of avoiding glycaemic variability and hypoglycaemia
  • The use of continuous glucose monitoring (CGM) and interpretation of time-in-range (TIR) data to improve diabetes care
  • The clinical evidence supporting second-generation basal insulin analogues for improving glucose variability control/TIR in patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM)
  • Practical, actionable clinical practice pointers for identifying those patients who will benefit most from second-generation basal analogue insulin therapy and the manner in which those patients who are currently using other insulin treatments can safely switch therapies.
ATTENTIONLAST CHANCE - This module will be leaving on 31 July 2025

To access this module, please register or login: